How are the treatment strategies for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) evolving? This paper discusses the latest recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL, which are different manifestations of the same disease. It highlights key molecular and cytogenetic variables with prognostic implications, emphasizing the importance of undetectable minimal residual disease after treatment. The guidelines address the selection of treatment based on various factors, including disease stage, genetic mutations, patient age, and overall health. By providing a comprehensive overview of current best practices, this manuscript serves as a valuable resource for healthcare professionals involved in the care of patients with CLL/SLL.
As a publication of the Journal of the National Comprehensive Cancer Network, this article directly aligns with the journal's focus on providing practical guidelines for cancer management. The paper's emphasis on treatment recommendations and prognostic factors is highly relevant to the journal's audience of oncologists and healthcare professionals. The comprehensive nature of the guidelines ensures their significance within the field of oncology.